Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
19 Abril 2023 - 6:05AM
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical
company revolutionizing the delivery of therapies to the back of
the eye through the suprachoroidal space (SCS®), announced today
that multiple poster presentations will be given on the Company’s
suprachoroidal injection delivery platform at The Association for
Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
taking place April 23-27, 2023, in New Orleans, LA.
Title: Safety and Tolerability Study of
Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients with
Persistent Activity Following Anti-VEGF Therapy (OASIS,
NCT04626128; Extension Study NCT05131646) Lead
Author: Dennis M. Marcus, M.D. Southeast Retina CenterDate: Sunday,
April 23, 2023Time: 12:00 pm – 1:45 pm CT
Title: Suprachoroidal delivery of
CLS-301, a potent small molecule integrin antagonist, offers
multimonth durability and high bioavailability in the
chorioretina Lead Author: Viral
Kansara, Ph.D., Vice President, Preclinical Development, Clearside
Biomedical Date: Tuesday, April 25, 2023Time: 8:45 am – 10:30 am
CT
Title: Early Adoption of Triamcinolone
Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A
Physician Survey Lead Author: Peter Yuwei Chang,
M.D., Massachusetts Eye Research and Surgery InstitutionDate:
Tuesday, April 25, 2023Time: 3:30 pm – 5:00 pm CT
About Clearside’s Suprachoroidal Space
(SCS®) Injection Platform and SCS
Microinjector®
Clearside’s patented, proprietary suprachoroidal
space (SCS®) injection treatment approach offers unprecedented
access to the back of the eye where sight-threatening disease often
occurs. The Company’s unique platform is inherently flexible and
intended to work with established and new formulations of
medications. Clearside’s proprietary SCS Microinjector® can be
used to deliver a wide variety of drug candidates into the
suprachoroidal space, providing targeted delivery to potentially
improve efficacy and compartmentalization of medication to reduce
or eliminate toxic effects on non-diseased cells. The SCS
Microinjector system is composed of a syringe, a custom-designed
hub and two 30-gauge hollow microneedles of varying lengths, each
less than 1.2 millimeters, optimizing insertion and suprachoroidal
administration of drugs.
About CLS-AX (axitinib injectable
suspension)
CLS-AX (axitinib injectable suspension) is an
investigational proprietary suspension of axitinib for
suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor
(TKI), currently approved as an oral tablet formulation to treat
advanced renal cell carcinoma, that achieves pan-VEGF blockade,
directly inhibiting VEGF receptors-1, -2, and -3 with high potency
and specificity. Clearside believes this broad VEGF blockade may
have efficacy advantages over existing retinal therapies by acting
at a different level of the angiogenesis cascade and may benefit
patients who sub-optimally respond to current, more narrowly
focused anti-VEGF therapies. Suprachoroidal injection of this
proprietary suspension of axitinib has demonstrated meaningful
potential in preclinical studies in multiple species and in a Phase
1/2a wet AMD clinical trial, in which CLS-AX was well tolerated and
demonstrated an excellent safety profile. With suprachoroidal
administration of axitinib, Clearside believes there is the
potential to achieve prolonged duration and targeted delivery to
affected tissue layers. Clearside is developing CLS-AX as a
long-acting therapy for the treatment of retinal diseases.
About Clearside Biomedical,
Inc.
Clearside Biomedical, Inc. is a
biopharmaceutical company revolutionizing the delivery of therapies
to the back of the eye through the suprachoroidal space (SCS®).
Clearside’s SCS injection platform, utilizing the Company’s
proprietary SCS Microinjector®, enables an in-office, repeatable,
non-surgical procedure for the targeted and compartmentalized
delivery of a wide variety of therapies to the macula, retina or
choroid to potentially preserve and improve vision in patients with
sight-threatening eye diseases. Clearside is developing its own
pipeline of small molecule product candidates for administration
via its SCS Microinjector. The Company’s lead program, CLS-AX
(axitinib injectable suspension), for the treatment of neovascular
age-related macular degeneration (wet AMD), is in Phase 2 clinical
testing. Clearside developed and gained approval for its first
product, XIPERE® (triamcinolone acetonide injectable
suspension) for suprachoroidal use, which is available in the U.S.
through a commercial partner. Clearside also strategically partners
its SCS injection platform with companies utilizing other
ophthalmic therapeutic innovations. For more information, please
visit www.clearsidebio.com.
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words such as “believe”, “expect”, “may”, “plan”,
“potential”, “will”, and similar expressions, and are based on
Clearside’s current beliefs and expectations. These forward-looking
statements include statements regarding the clinical development,
and the potential benefits, of CLS-AX and therapies using
Clearside’s SCS Microinjector®. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected in such statements. Risks and uncertainties
that may cause actual results to differ materially include
uncertainties inherent in the conduct of clinical trials,
Clearside’s reliance on third parties over which it may not always
have full control and other risks and uncertainties that are
described in Clearside’s Annual Report on Form 10-K for the year
ended December 31, 2022, filed with the U.S. Securities and
Exchange Commission (SEC) on March 14, 2023 and Clearside’s other
Periodic Reports filed with the SEC. Any forward-looking statements
speak only as of the date of this press release and are based on
information available to Clearside as of the date of this release,
and Clearside assumes no obligation to, and does not intend to,
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor and Media Contacts:Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024